PMID- 28260511
OWN - NLM
STAT- MEDLINE
DCOM- 20180416
LR  - 20180416
IS  - 1996-3181 (Electronic)
IS  - 1871-5273 (Linking)
VI  - 16
IP  - 4
DP  - 2017
TI  - Clinically Relevant Drug Interactions with Anti-Alzheimer's Drugs.
PG  - 501-513
LID - 10.2174/1871527316666170303144817 [doi]
AB  - BACKGROUND: The aging world population had led to an increase in the prevalence 
      of Alzheimer's disease (AD). The drugs used to slow down the onset of AD, 
      galantamine, donepezil, rivastigmine and memantine, are generally well-tolerated. 
      However, drug interactions between these drugs and other drugs are an important 
      aspect of patient safety that should be borne in mind, particularly given the 
      high burden of polypharmacy in the elderly. The aim of this review is to provide 
      an updated review of clinically significant drug-drug interactions concerning 
      drugs approved for AD. METHOD: PubMed was searched for relevant keywords. No time 
      limit was imposed but only articles in English published in peer-reviewed 
      journals were selected. Relevant literature was also identified from the 
      references of identified articles. Further information was obtained from drug 
      summary of product characteristics. RESULTS: The major pharmacokinetic 
      interactions identified concerned fluoxetine, paroxetine and ketoconazole when 
      used with galantamine or donepezil. On the other hand, the major potential 
      pharmacodynamic interactions concerned anti-dementia drugs and general anesthesia 
      agents, anti-cholinergic drugs, conventional antipsychotics and 
      bradycardia-inducing drugs. In clinical practice memantine shows a lower 
      potential for pharmacodynamic drug-drug interactions (DDIs) compared to other 
      drug classes. CONCLUSION: The concomitant use of anti-dementia drugs with other 
      drugs can have variable clinical effects, making appropriate prescribing of these 
      drugs very challenging. A simple and coherent way of presenting evidence on 
      complex drug interaction information from heterogenous sources to clinicians is 
      needed in order for the voluminous data available to have an impact on clinical 
      practice.
CI  - Copyright(c) Bentham Science Publishers; For any queries, please email at 
      epub@benthamscience.org.
FAU - Caraci, Filippo
AU  - Caraci F
AD  - Department of Drug Sciences, University of Catania, Viale Andrea Doria 6, 95125 
      Catania, Italy.
FAU - Sultana, Janet
AU  - Sultana J
AD  - Department of Clinical and Experimental Medicine, University of Messina, Italy.
FAU - Drago, Filippo
AU  - Drago F
AD  - Department of Biomedical and Biotechnological Sciences, University of Catania, 
      Catania, Italy.
FAU - Spina, Edoardo
AU  - Spina E
AD  - Department of Clinical and Experimental Medicine, University of Messina, Italy.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United Arab Emirates
TA  - CNS Neurol Disord Drug Targets
JT  - CNS & neurological disorders drug targets
JID - 101269155
RN  - 0 (Nootropic Agents)
SB  - IM
MH  - Alzheimer Disease/*drug therapy
MH  - Animals
MH  - Drug Interactions
MH  - Humans
MH  - Nootropic Agents/*therapeutic use
OTO - NOTNLM
OT  - Alzheimer's disease
OT  - cholinesterase inhibitors
OT  - drug interactions
OT  - memantine
OT  - pharmacodynamics
OT  - pharmacokinetics
EDAT- 2017/03/07 06:00
MHDA- 2018/04/17 06:00
CRDT- 2017/03/07 06:00
PHST- 2016/11/15 00:00 [received]
PHST- 2017/01/18 00:00 [revised]
PHST- 2017/02/01 00:00 [accepted]
PHST- 2017/03/07 06:00 [pubmed]
PHST- 2018/04/17 06:00 [medline]
PHST- 2017/03/07 06:00 [entrez]
AID - CNSNDDT-EPUB-82113 [pii]
AID - 10.2174/1871527316666170303144817 [doi]
PST - ppublish
SO  - CNS Neurol Disord Drug Targets. 2017;16(4):501-513. doi: 
      10.2174/1871527316666170303144817.